From $1.2M ARR today to global public holding.
RobGenes is already revenue-generating ($100K/month, 3,000+ patients, anchor hospitals in UAE & KSA). The Pre-Seed phase is complete and bootstrapped. The Seed round below is the entry point for outside investors — at de-risked terms because revenue, customers and clinical validation already exist. Hover any phase for details.
Strategic Angel / Pre-Seed — Completed
In plain words
Already executed. The founders bootstrapped the company, built the platform, signed the first hospitals (Dubai London Hospital, Aster, Savoy, Lifespan) and reached ~$100K/month in revenue with 3,000+ patients — without giving up any equity to outside investors.
Why investors come in: Validated the science, the product and the commercial model in one of the most demanding healthcare markets in the world (UAE & KSA).
Seed — Current Round
In plain words
The round you can join today. Because the company is already generating ~$1.2M ARR with anchor hospitals, this is a Seed at de-risked terms — not a typical pre-revenue Seed. Capital accelerates expansion across the Gulf, Europe and Latin America.
Why investors come in: Scale a working revenue engine: more patients per existing clinic, more clinics per country, more countries.
Series A
In plain words
First true venture capital round. Funds invest after the company proves it scales repeatably across geographies. Money is used to industrialize what already works.
Why investors come in: Scale the AI platform, hire commercial leadership and dominate priority regions.
Series B
In plain words
Growth capital. Larger funds and strategic players (pharma, lab groups, longevity brands) join to accelerate global expansion and acquire smaller competitors.
Why investors come in: Become the category leader in AI-driven precision longevity in priority regions.
Series C
In plain words
Late-stage capital. Crossover and growth funds prepare the company for a public listing or a major strategic exit. Often includes secondary sales for early investors.
Why investors come in: Industrialize operations, secure payor/insurance partnerships and prepare audited financials for IPO.
IPO — Public Offering
In plain words
The company sells shares to the public on a stock exchange. Anyone can buy. Early investors gain liquidity, the company raises a large amount of capital and the brand reaches global recognition.
Why investors come in: Unlock liquidity for early investors, raise long-term capital and use public stock as currency for acquisitions.
Post-IPO · Global Holding
In plain words
The next chapter. As a public holding, RobGenes acquires complementary companies, launches new verticals and consolidates the global longevity market. Possible alternative: full acquisition by a pharma or tech giant.
Why investors come in: Become the global standard for AI precision health and consolidate the longevity industry.